临床试验汇总（Clinical trial summary）.doc

临床试验汇总（Clinical trial summary） ESC2008 clinical trial summary The author of hebei provincial peoples hospital: guo yifang zhang qianhui Key words: guo yifang 2008ESC aspirin clopidogrel drug for myocardial infarction ACEI A series of clinical trials have been unveiled at the just-concluded ESC2008 conference. These findings provide a great deal of new evidence for the diagnosis and treatment of cardiovascular diseases. The main research results are summarized as follows: 1. 3 t / 2 r Study design. A filter from the patients treated with PCI and/or clopidogrel to aspirin resistance, and randomly divided into two groups, respectively, for had class (n = 132) or placebo (n = 131), followed up for 30 days. The results of the study: 1. The 48 hours after treatment, the troponin I or T exceeded the normal upper limit of 3 times: 20% of tironon-group group was 35% (p = 0.009) for the placebo group; 2. 30 days of major adverse cardiac events (MACE) : 21% to 37% (p = 0.006); 3. TIMI severe bleeding at 30 days: 0 to 0. Conclusion: 1. In patients with PCI after aspirin or/and clopidogrel resistance, the incidence of myocardial infarction in 48 hours was helpful for the use of tirofiban. 2. No severe bleeding occurred in the two groups of patients with MACE at 30 days. 2. APPRAISE - 1 Study design: patients with stable ACS were randomly divided into three groups, which received apixaban 10mg 1 / day (n = 318), apixaban 2.5 mg 2 / day (n = 317), and placebo (n = 611) for a period of six months. Results: 1. The primary end point ISTH severe bleeding or have clinical significance of mild-to-moderate hemorrhage: 10 mg/day group 1 and 2.5 2 mg/day or placebo group were 7.9%, 5.7%, 3% (10 mg group and comfort unit p = 0.005, 2.5 magnesium 2 / day group and placebo group (p = 0.09). 2. Secondary endpoint death, myocardial infarction, ischemia or stroke: 3 groups were 6.0%, 7.6%, 8.7% (10mg group and placebo group p = 0.07, 2.5mg2 / day group and placebo group p = 0.21). Conclusion: 1.